Phaseline

Targets › IL12B

IL12B (Interleukin-12 subunit beta): drug programs, companies and trials

9 programs from 8 companies in 158 trials: 49 Phase 2, 43 Phase 4, 42 Phase 3, 24 Phase 1; Immunology, Other, Gastroenterology; next expected readout Dec 2026.

Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC..; FUNCTION: Associates with IL23A to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral…. (UniProt, P29460)

Open in Phaseline: the race on IL12B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
University of CalgaryCBD 100 mg OD
Interleukin-23 inhibitor
CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1Phase 4Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope …Dec 2026
Johnson & Johnson (Janssen)Guselkumab (CNTO1959)
Interleukin-23 inhibitor
IL12B, IL23APhase 4Arthritis, Psoriatic; Psoriasis; Colitis, Ulcerative; Crohn's Disease …Dec 2026
Eli LillyMirikizumab (LY3074828)
Interleukin-23 inhibitor
IL12B, IL23APhase 4Lactation; Crohn's Disease; Ulcerative Colitis; Colitis, Ulcerative …Feb 2027
AbbVieRisankizumab
Interleukin-23 inhibitor
IL12B, IL23APhase 3Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Crohn's Disease (CD) …Jan 2027
Sun Pharmaceutical IndustriesTildrakizumab
Interleukin-23 inhibitor
IL12B, IL23APhase 3Active Psoriatic Arthritis; Moderate to Severe Genital Psoriasis; Psoriatic Arthritis; Moderate-to-severe Chronic Plaque PsoriasisFeb 2027
Johnson & Johnson (Janssen)Ustekinumab
Interleukin-12 inhibitor; Interleukin-23 inhibitor
IL12B, IL12A, IL23APhase 3Crohn Disease; Psoriasis; Crohn Disease (CD); Type 1 Diabetes Mellitus …Sep 2027
University Health Network, TorontoICG dye
Interleukin-12 produced by genetically modified AML cells; immune stimulatory cytokine
IL12A, IL12BPhase 2All Solid Tumors; Surgery Site Fistula; Acute Myeloid Leukemia; Melanoma (Skin)Dec 2026
PhilogenIL12-L19L19
Antibody-cytokine fusion protein; IL-12 fused to L19 antibody targeting fibronectin
IL12A, IL12B, FN1Phase 1Advanced Solid TumorDec 2026

Conditions

Crohn's Disease (11) Ulcerative Colitis (9) Crohn Disease (9) Psoriasis (8) Psoriatic Arthritis (4) Colitis, Ulcerative (3) Crohn Disease (CD) (3) Psoriasis Vulgaris (3) Nicotine Dependence (3) Ulcerative Colitis (UC) (2) Pouchitis (2) Arthritis, Psoriatic (2)

Modalities

antibody (5), small molecule (2), protein or peptide (1)

Companies

Johnson & Johnson (Janssen) (2) AbbVie (1) Eli Lilly (1) Sun Pharmaceutical Industries (1) University of California, San Francisco (1) University of Calgary (1) Philogen (1) University Health Network, Toronto (1)

Related targets

IL23A (7) IL12A (3) ADRB2 (2) NR3C1 (2) HTR2A (2) AGTR1 (1) PDCD1 (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1) CHRM3 (1) CHRM2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.